A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blocking negative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrations considerably higher than plasma levels achieved by clinically effective dosing, the anti-CTLA-4 antibody Ipilimumab blocks neither B7 trans-endo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Res
Hlavní autoři: Du, Xuexiang, Tang, Fei, Liu, Mingyue, Su, Juanjuan, Zhang, Yan, Wu, Wei, Devenport, Martin, Lazarski, Christopher A, Zhang, Peng, Wang, Xu, Ye, Peiying, Wang, Changyu, Hwang, Eugene, Zhu, Tinghui, Xu, Ting, Zheng, Pan, Liu, Yang
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5939050/
https://ncbi.nlm.nih.gov/pubmed/29472691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41422-018-0011-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky